What is 1910 Genetics?
Founded in 2018, 1910 Genetics is a biotechnology company dedicated to identifying and developing therapeutics for targets that possess clinical or genetic validation. The company leverages its expertise to advance novel treatments, positioning itself within the competitive landscape of precision medicine and drug discovery. The recent influx of capital is expected to accelerate its research and development initiatives.
How much funding has 1910 Genetics raised?
1910 Genetics has raised a total of $47.7M across 2 funding rounds:
Series A
$22M
Stock Offering
$25.7M
Series A (2021): $22M with participation from Playground and M12
Stock Issuance/Offering (2021): $25.7M, investors not publicly disclosed
Key Investors in 1910 Genetics
Playground
Playground is an investment firm that likely focuses on early-stage technology and life sciences companies, providing the necessary capital and strategic guidance for growth.
M12
M12, Microsoft's Venture Fund, invests in enterprise software companies primarily in the Series A through C funding stages with a focus on applied AI, business applications, infrastructure, security, and vanguard technologies. As part of its value-add to portfolio companies, M12 offers unique access to strategic go-to-market resources and relationships globally.
What's next for 1910 Genetics?
With a major strategic investment bolstering its financial standing, 1910 Genetics is poised for accelerated growth and expansion. This significant backing, categorized as enterprise-level funding, suggests the company is moving towards scaling its operations, potentially advancing its lead candidates through clinical trials, and further solidifying its market position. The strategic nature of the investment may also indicate partnerships or collaborations aimed at enhancing its therapeutic pipeline and market reach.
See full 1910 Genetics company page
